As per its 2Q15 earnings report, Novavax’s (NVAX) total revenue has gone up by 41.70% from 1Q15 driven by successful clinical tests of new drugs. Novavax has gotten positive results from clinical trials on drugs to treat Ebola and seasonal influenza.
Gross margins rise from successful clinical tests
The gross margin for Novavax was 80.80%. Gross margins for its competitors Vical (VICL), Biota Pharmaceuticals (BOTA), Merck & Co. (MRK), Sinovac Biotech, and AstraZeneca (AZN) were 43.03%, 94.92%, 62.71%, 73.74%, and 84%, respectively. This shows that Novavax has performed well as compared to its competitors. The PowerShares Dynamic Pharmaceuticals ETF (PJP) has 5.15% of its holding in Novavax.
Novavax is a clinical-stage vaccine company. Its main focus point is on discovery, maturation, and commercialization of recombinant nanoparticle and adjuvants. The company targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus, seasonal influenza, pandemic flu, and ebola virus. The company’s recombinant nanoparticles and Matrix-M adjuvant technology aim to improve human health and safety.